The FINANCIAL — Roche today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth of Roche’s haematology portfolio and pipeline, and commitment to developing innovative treatment solutions for patients in need.
“We have one of the largest clinical development programmes in malignant and non-malignant haematology and we continuously seek to improve patient outcomes by exploring new therapeutic mechanisms, combinations and clinical trial endpoints,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Our data reflect our ongoing commitment to following the science and improving the lives of patients with some of the most difficult-to-treat blood disorders.”
Building on its 20-year legacy in antibody engineering, Roche is exploring novel mechanisms of action for immunotherapies including T-cell engaging bispecific antibodies. Data on three investigational bispecifics will be presented, including:
- Progress from Roche’s CD20xCD3 bispecific antibody development programmes, including updated results for mosunetuzumab in relapsed or refractory (R/R) follicular lymphoma and early data in first-line diffuse large B-cell lymphoma (DLBCL). Additionally, data demonstrating high response rates with step-up dosing of glofitamab in people with R/R NHL will be presented.
- First clinical safety, efficacy and biomarker data from cevostamab (BFCR4350A), a first-of-its-kind FcRH5xCD3 bispecific antibody targeting FcRH5 on myeloma cells and CD3 on T-cells, will be presented, with initial results from the ongoing phase I GO39775 dose-escalation study in people with heavily pre-treated R/R MM.
Roche will also be sharing longer-term data, including results on novel clinical trial endpoints, that support the known efficacy and safety of its established medicines, including:
- Three year follow-up data from the pivotal phase III HAVEN study programme (HAVEN 1-4 studies), reinforcing the efficacy and safety profile of Hemlibra® (emicizumab) in people with haemophilia A with and without factor VIII inhibitors.
- Results from the first interim analysis of the European Haemophilia Safety Surveillance database, examining real-world data to monitor the ongoing safety of Hemlibra in people with haemophilia A with and without factor VIII inhibitors.
- Results on fixed-duration, chemotherapy-free combinations in chronic lymphocytic leukaemia (CLL), including five-year analysis of the phase III MURANO study, investigating Venclexta®/Venclyxto® (venetoclax) plus MabThera®/Rituxan® (rituximab) in R/R CLL, with updates on minimal residual disease and long-term outcomes analysis. Venclexta/Venclyxto is being developed by AbbVie and Roche.
- Updated results from the phase Ib/II randomised GO29365 study of fixed-duration Polivy® (polatuzumab vedotin), plus bendamustine and MabThera/Rituxan, in people with R/R DLBCL, including preliminary results from a single-arm extension cohort of 106 additional patients.
Key abstracts featuring Roche medicines that will be presented at ASH can be found in the table below.
| Medicine | Abstract title | Abstract number/presentation details |
| Mosunetuzumab (investigational) | Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial | #702 oral presentation Session: 623 Monday 7 December 2020 13:30-15.00 PT (presentation time 14.00 PT) |
| Single-agent Mosunetuzumab is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B‑Cell Lymphoma | #401 oral presentation Session: 626 Sunday 6 December 2020 12:00-13:30 PT (presentation time 12:15 PT) | |
| Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination With CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma | #1184 poster presentation Session: 626 Saturday 5 December 2020 07:00-15:30 PT | |
| Glofitamab (investigational) | Glofitamab Step-Up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma | #403 oral presentation Session: 626 Sunday 6 December 2020 12:00-13:30 PT (presentation time 12.45 PT) |
| Cevostamab (BFCR4350A; a FcRH5xCD3 bispecific antibody) (investigational) | Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma | #292 oral presentation Session: 653 Saturday 5 December 2020 14:00-15.30 PT (presentation time 14.30 PT) |
| Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma | #3213 poster presentation Session: 653 Monday 7 December 2020 07:00-15.30 PT | |
| Hemlibra (approved use) | Safety and Efficacy of Emicizumab in Persons with Hemophilia A With or Without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4) | #1800 poster presentation Session: 322 Sunday 6 December 2020 07:00-15:30 PT |
| Real-World Safety of Emicizumab: The First Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database | #2685 poster presentation Session: 322 Monday 7 December 2020 07:00-15:30 PT | |
| Venclexta/Venclyxto (approved use) | Five-Year Analysis of MURANO Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx) | #125 oral presentation Session: 642 Saturday 5 December 2020 09:30-11:00 PT (presentation time 10:00 PT) |
| Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 trial | #127 oral presentation Session: 642 Saturday 5 December 2020 09:30-11:00 PT (presentation time 10:30 PT) | |
| Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 mutations | #1904 poster presentation Session: 613 Sunday 6 December 2020 07:00-15:30 PT | |
| Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations | #461 oral presentation Session: 613 Sunday 6 December 2020 14:00-15:30 PT (presentation time 14:45 PT) | |
| Characteristics and Outcome of Patients with Chronic Lymphocytic Leukaemia and Partial Response to Venetoclax-Obinutuzumab | #1310 poster presentation Session: 642 Saturday 5 December 2020 07:00-15:30 PT | |
| Polivy (approved use) | Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension | #3020 poster presentation Session: 626 Monday 7 December 2020 07:00-15:30 PT |
| Risk Profiling of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients By Measuring Circulating Tumor DNA | #532 oral presentation Session: 627 Monday 7 December 2020 07:00-08:30 PT (presentation time 07:30 PT) |
